Suven Life Sciences announces five poster presentations at SLEEP 2020 virtual conference
Hyderabad: Suven Life Sciences has announced that five posters on SUVN-G3031, a histamine-3 receptor inverse agonist will be presented at the upcoming 34thAnnual Meeting of the Associated Professional Sleep Societies (APSS), known as "SLEEP 2020." The meeting will be held virtually from August 27-30, 2020.
The poster presentations include a Phase-2 proof-of-concept study design that is currently recruiting the patients with narcolepsy with and without cataplexy, pharmacokinetic profile and safety findings from Phase-1 study, preclinical efficacy and differentiating features over current treatments of narcolepsy.
Details of the poster presentations are as below:
• Phase-2 proof of concept study of SUVN-G3031, a histamine H3 receptor inverse aagonist for the potential treatment of narcolepsy (Poster 0759)
• SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist: Safety, tolerability and pharmacokinetics following single and multiple ascending doses in healthy adult subjects (Poster 0760)
• SUVN-G3031, A histamine H3 receptor inverse agonist produces robust wake promoting and anticataplectic activity in orexin knockout mice (Poster 0008)
• Preclinical characterization of SUVN-G3031, A histamine H3 receptor inverse agonist for the treatment of narcolepsy (Poster 0072)
• SUVN-G3031, A potent and selective histamine H3 receptor inverse agonist - Differentiating features over current treatments of narcolepsy (Poster 0155)
Update on SUVN-G3031 Phase-2 proof-of-concept study:
• Patient recruitment for the study is currently ongoing in USA.
• Data readout from Phase-2 POC study is estimated in early 2021.
SUVN-G3031 is being evaluated as monotherapy for the safety, tolerability, pharmacokinetics, and efficacy at doses of 2 mg and 4 mg compared to placebo in patients with narcolepsy with and without cataplexy. The primary objective of this study is to demonstrate superiority of SUVN-G3031 compared to placebo as measured by an improvement in the Maintenance of Wakefulness Test (MWT) score.
